Diffuse intravascular coagulation is induced by different causes, and the severity of clinical manifestations varies, and the treatment should be individualized according to the patient’s etiology, as follows: 1, treatment of underlying diseases: eliminating the triggers that cause DIC, sepsis caused by the need to fight infection, tumor caused by the treatment of tumors, and pathological obstetrics caused by the timely correction of the fundamental measures for the treatment of DIC; 2, anticoagulant therapy: it must be carried out simultaneously with supplemental coagulation factors under the premise of treating underlying diseases, and used in the early stage of DIC, that is, the hypercoagulable stage. Anti-coagulation therapy: it must be carried out under the premise of treating the underlying disease and synchronized with the supplementation of coagulation factors, and is used in the early stage of DIC, that is, in the hypercoagulable stage. The most commonly used drug is heparin, including ordinary heparin and low molecular heparin. Do not use anticoagulation if the patient already has diffuse bleeding, hemorrhage, or when DIC is caused by snakebite, or if the patient is already in the advanced stage of DIC; 3. Alternative treatment: if the patient has platelet and coagulation factor consumption in the course of DIC, supplementation of coagulation factors, plasma, or fibrinogen should be done in a timely manner; 4. Fibrinolytic inhibitor: it is relatively rare unless there is obvious Hyperfibrinolysis, for example, patients with promyelocytic leukemia obviously combined with hyperfibrinolysis, can be used.